Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Sarcoma 1Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 13Neoplasm Metastasis 9Stomach Neoplasms 5Endometrial Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Adenocarcinoma 3Salivary Gland Neoplasms 2Prostatic Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Melanoma 1

Interventions

Bevacizumab 32Cetuximab 28Fluorouracil 26Leucovorin 24Specimen Handling 23Oxaliplatin 23pembrolizumab 18Biopsy 16Magnetic Resonance Spectroscopy 14Irinotecan 13Nivolumab 9atezolizumab 7Folfox protocol 7fludarabine 6balstilimab 6Pemetrexed 6Panitumumab 6Cyclophosphamide 6Cisplatin 6Carboplatin 6Capecitabine 6trifluridine tipiracil drug combination 5encorafenib 5Standard of Care 5IFL protocol 5HMPL-013 5Gemcitabine 5dehydroftorafur 4Immunoglobulin G 4Disulfides 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colorectal Neoplasms × trastuzumab deruxtecan × 30 days × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡